Clinical study for endostatin combined with concurrent chemoradiotherapy for cervical cancer stage IIb-IVa in intravenous pump-focused group

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900025924

Enrollment

Unknown

Registered

2019-09-14

Start date

2020-01-01

Completion date

Unknown

Last updated

2019-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cervical carcinoma

Interventions

single arm:Synchronized radiochemical combined Endor

Eligibility

Sex/Gender

Female

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Only those who satisfy all the following items can be included in the group test: 1) Aged 18-70 years; 2) Eastern Cancer Cooperative Group (ECOG) Physical Status Score (PS) 0-1; 3) Initial treatment of cervical squamous cell carcinoma confirmed by pathology and/or cytology; 4) Clinical stage IIb-IVa (FIGO stage); 5) At least one measurable lesion has measurable tumor lesions (according to RECIST 1.1 standard); 6) Laboratory chemotherapy indicators must meet the following criteria, blood routine, liver, kidney function and cardiac function are basically normal. Leukocyte (>4.0 *10^9/L), neutrophil (>2.0 *10^9/L), platelet (>100 *10^9/L), hemoglobin (>90 g/L), serum bilirubin (>1.5 times of the maximum normal value), ALT and AST (>1.5 times of the maximum normal value). 7) Expected survival beyond 3 months. 8) Understand the situation of this study and have signed the informed consent.

Exclusion criteria

Exclusion criteria: Patients with any of the following items will not be eligible for this study: 1) Previous allergic reactions to biological agents. 2) Other anti-cancer treatments are under way. 3) Distant metastasis (including para-aortic lymph node metastasis). 4) There are one of the following situations: patients with major organ dysfunction and serious heart diseases, including congestive heart failure, uncontrollable arrhythmia, angina, valvular disease, myocardial infarction and intractable hypertension requiring long-term drug treatment, pregnant or lactating women, and patients with persistent infectious wounds. Researchers do not think it is suitable for participants in this study.

Design outcomes

Primary

Measure	Time frame
ORR;	—

Countries

China

Contacts

Public ContactLiu Yun

Army Characteristic Medical Center (Daping Hospital)

1063045355@qq.com+86 17783046113

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026